200 related articles for article (PubMed ID: 25963568)
1. Evaluating Potential P-gp Substrates: Main Aspects to Choose the Adequate Permeability Model for Assessing Gastrointestinal Drug Absorption.
da Silva Junior JB; Dezani TM; Dezani AB; dos Reis Serra CH
Mini Rev Med Chem; 2015; 15(10):858-71. PubMed ID: 25963568
[TBL] [Abstract][Full Text] [Related]
2. Role of P-glycoprotein-mediated secretion in absorptive drug permeability: An approach using passive membrane permeability and affinity to P-glycoprotein.
Döppenschmitt S; Spahn-Langguth H; Regårdh CG; Langguth P
J Pharm Sci; 1999 Oct; 88(10):1067-72. PubMed ID: 10514357
[TBL] [Abstract][Full Text] [Related]
3. Examining P-gp efflux kinetics guided by the BDDCS - Rational selection of in vitro assay designs and mathematical models.
Riede J; Umehara KI; Schweigler P; Huth F; Schiller H; Camenisch G; Poller B
Eur J Pharm Sci; 2019 Apr; 132():132-141. PubMed ID: 30857914
[TBL] [Abstract][Full Text] [Related]
4. Novel experimental parameters to quantify the modulation of absorptive and secretory transport of compounds by P-glycoprotein in cell culture models of intestinal epithelium.
Troutman MD; Thakker DR
Pharm Res; 2003 Aug; 20(8):1210-24. PubMed ID: 12948019
[TBL] [Abstract][Full Text] [Related]
5. Validation and application of Caco-2 assays for the in vitro evaluation of development candidate drugs as substrates or inhibitors of P-glycoprotein to support regulatory submissions.
Elsby R; Surry DD; Smith VN; Gray AJ
Xenobiotica; 2008 Jul; 38(7-8):1140-64. PubMed ID: 18668443
[TBL] [Abstract][Full Text] [Related]
6. Using the lentiviral vector system to stably express chicken P-gp and BCRP in MDCK cells for screening the substrates and studying the interplay of both transporters.
Zhang Y; Huang J; Liu Y; Guo T; Wang L
Arch Toxicol; 2018 Jun; 92(6):2027-2042. PubMed ID: 29725709
[TBL] [Abstract][Full Text] [Related]
7. Peptide transporter substrate identification during permeability screening in drug discovery: comparison of transfected MDCK-hPepT1 cells to Caco-2 cells.
Balimane PV; Chong S; Patel K; Quan Y; Timoszyk J; Han YH; Wang B; Vig B; Faria TN
Arch Pharm Res; 2007 Apr; 30(4):507-18. PubMed ID: 17489369
[TBL] [Abstract][Full Text] [Related]
8. Strategies to overcome simultaneous P-glycoprotein mediated efflux and CYP3A4 mediated metabolism of drugs.
Patel J; Mitra AK
Pharmacogenomics; 2001 Nov; 2(4):401-15. PubMed ID: 11722289
[TBL] [Abstract][Full Text] [Related]
9. Differential selectivity of efflux transporter inhibitors in Caco-2 and MDCK-MDR1 monolayers: a strategy to assess the interaction of a new chemical entity with P-gp, BCRP, and MRP2.
Mease K; Sane R; Podila L; Taub ME
J Pharm Sci; 2012 May; 101(5):1888-97. PubMed ID: 22359351
[TBL] [Abstract][Full Text] [Related]
10. Segmental dependent transport of low permeability compounds along the small intestine due to P-glycoprotein: the role of efflux transport in the oral absorption of BCS class III drugs.
Dahan A; Amidon GL
Mol Pharm; 2009; 6(1):19-28. PubMed ID: 19248230
[TBL] [Abstract][Full Text] [Related]
11. Efflux ratio cannot assess P-glycoprotein-mediated attenuation of absorptive transport: asymmetric effect of P-glycoprotein on absorptive and secretory transport across Caco-2 cell monolayers.
Troutman MD; Thakker DR
Pharm Res; 2003 Aug; 20(8):1200-9. PubMed ID: 12948018
[TBL] [Abstract][Full Text] [Related]
12. Commonly used surfactant, Tween 80, improves absorption of P-glycoprotein substrate, digoxin, in rats.
Zhang H; Yao M; Morrison RA; Chong S
Arch Pharm Res; 2003 Sep; 26(9):768-72. PubMed ID: 14560928
[TBL] [Abstract][Full Text] [Related]
13. Characterization of the efflux transporter(s) responsible for restricting intestinal mucosa permeation of the coumarinic acid-based cyclic prodrug of the opioid peptide DADLE.
Tang F; Borchardt RT
Pharm Res; 2002 Jun; 19(6):787-93. PubMed ID: 12134948
[TBL] [Abstract][Full Text] [Related]
14. Polymeric Drug-Delivery Systems: Role in P-gp Efflux System Inhibition.
Gupta P; Garg T; Tanmay M; Arora S
Crit Rev Ther Drug Carrier Syst; 2015; 32(3):247-75. PubMed ID: 26080810
[TBL] [Abstract][Full Text] [Related]
15. Small intestinal efflux mediated by MRP2 and BCRP shifts sulfasalazine intestinal permeability from high to low, enabling its colonic targeting.
Dahan A; Amidon GL
Am J Physiol Gastrointest Liver Physiol; 2009 Aug; 297(2):G371-7. PubMed ID: 19541926
[TBL] [Abstract][Full Text] [Related]
16. Quantitative evaluation of the function of small intestinal P-glycoprotein: comparative studies between in situ and in vitro.
Adachi Y; Suzuki H; Sugiyama Y
Pharm Res; 2003 Aug; 20(8):1163-9. PubMed ID: 12948013
[TBL] [Abstract][Full Text] [Related]
17. The Interactions of P-Glycoprotein with Antimalarial Drugs, Including Substrate Affinity, Inhibition and Regulation.
Senarathna SM; Page-Sharp M; Crowe A
PLoS One; 2016; 11(4):e0152677. PubMed ID: 27045516
[TBL] [Abstract][Full Text] [Related]
18. pH dependent uptake of loperamide across the gastrointestinal tract: an in vitro study.
Crowe A; Wong P
Drug Dev Ind Pharm; 2004 May; 30(5):449-59. PubMed ID: 15244080
[TBL] [Abstract][Full Text] [Related]
19. Computational models for identifying potential P-glycoprotein substrates and inhibitors.
Crivori P; Reinach B; Pezzetta D; Poggesi I
Mol Pharm; 2006; 3(1):33-44. PubMed ID: 16686367
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of P-glycoprotein-mediated renal drug interactions in an MDR1-MDCK model.
Karyekar CS; Eddington ND; Garimella TS; Gubbins PO; Dowling TC
Pharmacotherapy; 2003 Apr; 23(4):436-42. PubMed ID: 12680473
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
